Trial · NCT07910903
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
NCT07910903, Phase 3, Not yet recruiting, Keymed Biosciences Co.Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma. Trials, record NCT07910903. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910903
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- NCT number
- NCT07910903
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 320 participants, estimated
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Conditions
- Multiple Myeloma (MM)
- Interventions
- CM336, CM313, Daratumumab, Pomalidomide, Dexamethasone
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Frequency of Adverse Events (AEs) | Up to 4 years | An adverse event is any untoward medical occurrence in a study participant receiving study product, whether or not related to the product. Severity graded per CTCAE version 6.0. |
| Primary | Part 2: 9-Month Minimal Residual Disease (MRD) Negative Complete Response (CR) | At month 9 | MRD negative CR at Month 9 (±3 months) is defined as participants who have MRD negative status at Month 9±3 months (prior to progression or subsequent antimyeloma therapy) and have achieved CR or better per IMWG criteria at any time post-randomization up to Month 9±3 months. |
| Primary | Part 2: Progression Free Survival (PFS) | Up to 4 years | PFS is defined as the duration from the date of randomization to disease progression or death, whichever occurs first. Disease progression will be assessed according to IMWG criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910903
GET https://conductscience.org/api/trials/v1/NCT07910903/registered